Close Menu

SAN FRANCISCO (GenomeWeb) – University of Washington spinout Split Biosciences is commercializing a single-cell RNA sequencing technology that it aims to launch through an early-access program this summer.

The technology relies on fixing and immobilizing single cells, rather than physically isolating them, in order to do single-cell RNA sequencing. The startup, which currently has four full-time employees, raised around $1.2 million in seed financing last year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.

Sep
18
Sponsored by
Bionano Genomics

This webinar will outline how a team at Radboud University Medical Center is assessing ultra-long read optical mapping on the Bionano Saphyr system to replace classical cytogenetics approaches in routine testing and for the discovery of novel structural variants with potential scientific, prognostic, or therapeutic value that are missed by standard approaches.

Sep
25
Sponsored by
HalioDx

CAR T-cell therapy is an innovative form of immunotherapy that is finding increasing use for the management of blood cancers. 

Oct
01
Sponsored by
Thermo Fisher Scientific

This webinar will provide an overview of the sequencing capabilities of the Tumor Profiling Unit at the Institute for Cancer Research in London, with a focus on the lab's strategy for bringing in new genomics technologies.

Oct
03
Sponsored by
Agilent

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.